ClinicalTrials.govpublic full text
CS-121 APOC3 Base Editing in FCS
familial chylomicronemia syndrome (fcs), severe hypertriglyceridemia, acute pancreatitis, apolipoprotein c3 (apoc3), in vivo base editing, lipid nanoparticles (lnp), gene editing therapy, first-in-human study, rare metabolic disorder, interventional, early_phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 868094
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.